2019 ASH:阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期

2019-12-16 不详 MedSci原创

阿斯利康的BTK抑制剂Calquence在一项III期试验中结果显示了该药物对慢性淋巴细胞性白血病(CLL)患者无进展生存期(PFS)的影响。

阿斯利康的BTK抑制剂Calquence在一项III期试验中结果显示了该药物对慢性淋巴细胞性白血病(CLL)患者无进展生存期(PFS)的影响。

根据III期ELEVATE TN试验的中期分析,与先前未接受治疗的CLL患者中,与使用苯丁酸氮芥联合奥比妥单抗的标准治疗相比,Calquence(acalabrutinib)联合奥比妥单抗或作为单一疗法显着改善了患者PFS。

在美国奥兰多举行的2019年美国血液学学会年度会议上提供的数据表明,在28.3个月的中位随访中,与苯丁酸氮芥联合奥比妥珠单抗相比,该药物显着降低了疾病进展风险90%,死亡风险80%。

接受Calquence联合obinutuzumab治疗的患者中在24个月时无疾病进展或死亡占93%,而接受苯丁酸氮芥联合obinutuzumab治疗的患者,这一比例为47%。

AstraZeneca表示在ELEVATE TN试验中观察到的Calquence的安全性和耐受性特征与其已知特征一致。

Calquence是Bruton酪氨酸激酶(BTK)的抑制剂,它与BTK共价结合,从而抑制了其活性。在B细胞中,BTK信号传导是激活B细胞增殖,运输,趋化性和粘附所必需的途径。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1997967, encodeId=43cf199e96712, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Mar 08 11:20:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852213, encodeId=d9d218522135b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 19 15:20:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297384, encodeId=7bea129e3844b, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301296, encodeId=7a94130129631, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302284, encodeId=1546130228418, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378236, encodeId=083913e823612, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459678, encodeId=b03014596e89a, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59168, encryptionId=565f5916816, topicName=无进展生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c466182591, createdName=zhangfenasdf, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539103, encodeId=e313153910319, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598520, encodeId=e02b1598520cf, content=<a href='/topic/show?id=d79539964f' target=_blank style='color:#2F92EE;'>#Calquence#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3996, encryptionId=d79539964f, topicName=Calquence)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=885c18619437, createdName=karmond, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1997967, encodeId=43cf199e96712, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Mar 08 11:20:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852213, encodeId=d9d218522135b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 19 15:20:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297384, encodeId=7bea129e3844b, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301296, encodeId=7a94130129631, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302284, encodeId=1546130228418, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378236, encodeId=083913e823612, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459678, encodeId=b03014596e89a, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59168, encryptionId=565f5916816, topicName=无进展生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c466182591, createdName=zhangfenasdf, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539103, encodeId=e313153910319, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598520, encodeId=e02b1598520cf, content=<a href='/topic/show?id=d79539964f' target=_blank style='color:#2F92EE;'>#Calquence#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3996, encryptionId=d79539964f, topicName=Calquence)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=885c18619437, createdName=karmond, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=)]
    2020-09-19 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1997967, encodeId=43cf199e96712, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Mar 08 11:20:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852213, encodeId=d9d218522135b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 19 15:20:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297384, encodeId=7bea129e3844b, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301296, encodeId=7a94130129631, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302284, encodeId=1546130228418, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378236, encodeId=083913e823612, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459678, encodeId=b03014596e89a, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59168, encryptionId=565f5916816, topicName=无进展生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c466182591, createdName=zhangfenasdf, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539103, encodeId=e313153910319, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598520, encodeId=e02b1598520cf, content=<a href='/topic/show?id=d79539964f' target=_blank style='color:#2F92EE;'>#Calquence#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3996, encryptionId=d79539964f, topicName=Calquence)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=885c18619437, createdName=karmond, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1997967, encodeId=43cf199e96712, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Mar 08 11:20:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852213, encodeId=d9d218522135b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 19 15:20:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297384, encodeId=7bea129e3844b, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301296, encodeId=7a94130129631, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302284, encodeId=1546130228418, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378236, encodeId=083913e823612, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459678, encodeId=b03014596e89a, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59168, encryptionId=565f5916816, topicName=无进展生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c466182591, createdName=zhangfenasdf, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539103, encodeId=e313153910319, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598520, encodeId=e02b1598520cf, content=<a href='/topic/show?id=d79539964f' target=_blank style='color:#2F92EE;'>#Calquence#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3996, encryptionId=d79539964f, topicName=Calquence)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=885c18619437, createdName=karmond, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=)]
    2019-12-18 kksonne
  5. [GetPortalCommentsPageByObjectIdResponse(id=1997967, encodeId=43cf199e96712, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Mar 08 11:20:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852213, encodeId=d9d218522135b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 19 15:20:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297384, encodeId=7bea129e3844b, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301296, encodeId=7a94130129631, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302284, encodeId=1546130228418, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378236, encodeId=083913e823612, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459678, encodeId=b03014596e89a, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59168, encryptionId=565f5916816, topicName=无进展生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c466182591, createdName=zhangfenasdf, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539103, encodeId=e313153910319, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598520, encodeId=e02b1598520cf, content=<a href='/topic/show?id=d79539964f' target=_blank style='color:#2F92EE;'>#Calquence#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3996, encryptionId=d79539964f, topicName=Calquence)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=885c18619437, createdName=karmond, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1997967, encodeId=43cf199e96712, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Mar 08 11:20:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852213, encodeId=d9d218522135b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 19 15:20:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297384, encodeId=7bea129e3844b, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301296, encodeId=7a94130129631, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302284, encodeId=1546130228418, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378236, encodeId=083913e823612, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459678, encodeId=b03014596e89a, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59168, encryptionId=565f5916816, topicName=无进展生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c466182591, createdName=zhangfenasdf, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539103, encodeId=e313153910319, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598520, encodeId=e02b1598520cf, content=<a href='/topic/show?id=d79539964f' target=_blank style='color:#2F92EE;'>#Calquence#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3996, encryptionId=d79539964f, topicName=Calquence)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=885c18619437, createdName=karmond, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1997967, encodeId=43cf199e96712, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Mar 08 11:20:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852213, encodeId=d9d218522135b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 19 15:20:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297384, encodeId=7bea129e3844b, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301296, encodeId=7a94130129631, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302284, encodeId=1546130228418, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378236, encodeId=083913e823612, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459678, encodeId=b03014596e89a, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59168, encryptionId=565f5916816, topicName=无进展生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c466182591, createdName=zhangfenasdf, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539103, encodeId=e313153910319, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598520, encodeId=e02b1598520cf, content=<a href='/topic/show?id=d79539964f' target=_blank style='color:#2F92EE;'>#Calquence#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3996, encryptionId=d79539964f, topicName=Calquence)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=885c18619437, createdName=karmond, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1997967, encodeId=43cf199e96712, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Mar 08 11:20:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852213, encodeId=d9d218522135b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 19 15:20:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297384, encodeId=7bea129e3844b, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301296, encodeId=7a94130129631, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302284, encodeId=1546130228418, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378236, encodeId=083913e823612, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459678, encodeId=b03014596e89a, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59168, encryptionId=565f5916816, topicName=无进展生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c466182591, createdName=zhangfenasdf, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539103, encodeId=e313153910319, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598520, encodeId=e02b1598520cf, content=<a href='/topic/show?id=d79539964f' target=_blank style='color:#2F92EE;'>#Calquence#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3996, encryptionId=d79539964f, topicName=Calquence)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=885c18619437, createdName=karmond, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=)]
    2019-12-18 fengting7
  9. [GetPortalCommentsPageByObjectIdResponse(id=1997967, encodeId=43cf199e96712, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Mar 08 11:20:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852213, encodeId=d9d218522135b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Sep 19 15:20:00 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297384, encodeId=7bea129e3844b, content=<a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3772, encryptionId=d6b83e724b, topicName=BTK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301296, encodeId=7a94130129631, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302284, encodeId=1546130228418, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378236, encodeId=083913e823612, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459678, encodeId=b03014596e89a, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59168, encryptionId=565f5916816, topicName=无进展生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c466182591, createdName=zhangfenasdf, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539103, encodeId=e313153910319, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3771, encryptionId=6bce3e7106, topicName=BTK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61d813108447, createdName=fengting7, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598520, encodeId=e02b1598520cf, content=<a href='/topic/show?id=d79539964f' target=_blank style='color:#2F92EE;'>#Calquence#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3996, encryptionId=d79539964f, topicName=Calquence)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=885c18619437, createdName=karmond, createdTime=Wed Dec 18 04:20:00 CST 2019, time=2019-12-18, status=1, ipAttribution=)]
    2019-12-18 karmond

相关资讯

2019 ACEP:免疫治疗引起的胃肠道不良反应给急诊科医师带来了新的挑战

梅奥诊所的医学博士里士满·卡斯蒂略(Richmond Castillo)医师报道,在诊断中,急诊医师通常没有考虑与免疫疗法相关的AE。随着批准的免疫检查点抑制剂适应症清单的扩大,将来可能会有更多的患者前往急诊室就诊,这就是Castillo博士及其同事决定进行当前研究的原因。

2019 ESMO亚洲大会:国产曲妥珠单抗仿制药HLX02治疗乳腺癌在全球III期试验达到了主要终点

2019年ESMO亚洲大会上,根据一项大型的随机III期研究报告,在人类表皮生长因子受体2阳性(HER2 +)复发或先前未治疗的转移性乳腺癌女性中,复宏汉霖开发的曲妥珠单抗生物仿制药HLX02达到了与曲妥珠单抗相似的总体缓解率。

2019 AHA:阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善

阿斯利康(AstraZeneca)的新数据表明,与安慰剂相比,SGLT2抑制剂Farxiga(dapagliflozin)可以减轻恶化的心力衰竭(HF)(定义为住院、紧急就诊或因心血管事件致死)。

重磅!2019年国家优青名单正式出炉,625项获资助

11月12日,从国家自然科学基金委员会获悉,2019年国家优青获得者正式出炉。

定格2019:守护百姓健康 公共卫生事业筑起坚实“防线”

2019年7月,《健康中国行动(2019-2030年)》正式发布。这一国家战略,提出了健康知识普及、合理膳食、全面健身、控烟、心理健康促进、健康环境促进等十五大行动,政策重点正在从“治已病”向“治未病”转变。作为保障老百姓健康生活的重要屏障,公共卫生事业无疑是落实健康中国战略的重要着力点之一。这一年,在疫苗管理、传染病防控、控烟等公共卫生事项上的应对和突破,奏响了全面升级公卫服务的序章。疫苗法

中科院发布《2019 研究前沿》,新型 CRISPR 和环状 RNA 入选

近日,中国科学院科技战略咨询研究院、中国科学院文献情报中心与科睿唯安在北京联合向全球发布了《2019 研究前沿》报告和《2019 研究前沿热度指数》报告。